Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GOVX 
GeoVax Labs Inc (GOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.38
1 Year Target Price $11.38
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.36% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.29M USD | Price to earnings Ratio - | 1Y Target Price 11.38 |
Price to earnings Ratio - | 1Y Target Price 11.38 | ||
Volume (30-day avg) 4 | Beta 3.44 | 52 Weeks Range 0.73 - 11.18 | Updated Date 06/30/2025 |
52 Weeks Range 0.73 - 11.18 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -330.18% |
Management Effectiveness
Return on Assets (TTM) -915.19% | Return on Equity (TTM) -78814.56% |
Valuation
Trailing PE - | Forward PE 10.63 | Enterprise Value 13866596 | Price to Sales(TTM) 2.73 |
Enterprise Value 13866596 | Price to Sales(TTM) 2.73 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 15924600 | Shares Floating 13761977 |
Shares Outstanding 15924600 | Shares Floating 13761977 | ||
Percent Insiders 0.42 | Percent Institutions 7.72 |
Analyst Ratings
Rating 2 | Target Price 11.38 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GeoVax Labs Inc
Company Overview
History and Background
GeoVax Labs Inc. was founded in 2001 and focuses on developing immunotherapies and vaccines using its modified vaccinia Ankara (MVA)-VLP based vaccine platform. They've focused on infectious diseases and cancer vaccines.
Core Business Areas
- Vaccine Development: GeoVax develops vaccines for infectious diseases like HIV, Ebola, Marburg, Lassa fever, and Sudan fever, as well as cancer immunotherapies.
- Immunotherapy: They are developing cancer immunotherapies aimed at stimulating the immune system to fight cancer cells.
- Licensing and Collaboration: GeoVax collaborates with other organizations and licenses its technology for further development and commercialization.
Leadership and Structure
David Dodd is the Chairman and CEO. The company has a typical biotech structure with departments dedicated to research, development, clinical trials, and finance.
Top Products and Market Share
Key Offerings
- GV-NH6: A preventive HIV vaccine candidate in clinical trials. While specific market share data is unavailable due to the developmental stage, competitors in HIV vaccine development include Moderna (MRNA), Gilead Sciences (GILD), and Janssen (JNJ). No revenue to date.
- Cancer Immunotherapies: GeoVax is in early stages of development of cancer immunotherapies, so no market share data or revenue exists at this time. Competitors include Merck (MRK) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The vaccine and immunotherapy market is a rapidly growing sector driven by increasing global health concerns and technological advancements. High investment and R&D efforts characterize the market.
Positioning
GeoVax is a relatively small player focusing on niche vaccine and immunotherapy areas, using its MVA-VLP platform for specific diseases. Their advantage lies in their novel platform, but they face challenges in competing with larger, more established companies with greater resources.
Total Addressable Market (TAM)
The global vaccine market is projected to reach hundreds of billions of dollars. The immunotherapy market is also very high. GeoVax is positioned to capture a portion of this TAM through successful development and commercialization of its vaccine candidates, however, it must demonstrate strong results in clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary MVA-VLP vaccine platform
- Focus on unmet medical needs
- Experienced management team
- Potential for high-impact products
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
- Significant competition from larger companies
Opportunities
- Partnerships and collaborations
- Expanding vaccine market
- Government funding opportunities
- Advancements in vaccine technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Economic downturn affecting R&D funding
Competitors and Market Share
Key Competitors
- MRNA
- GILD
- JNJ
- MRK
- BMY
Competitive Landscape
GeoVax operates in a highly competitive landscape against larger, more established pharmaceutical companies. Its advantages are its novel technology platform and focus on specific unmet medical needs. Its disadvantages are its limited financial resources and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by grant funding and preclinical/clinical trial progress.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships.
Recent Initiatives: Focus on advancing HIV and cancer vaccine candidates through clinical trials and securing additional funding.
Summary
GeoVax Labs is a high-risk, high-reward biotech company with a promising vaccine platform but limited resources. Its success hinges on positive clinical trial results and securing strategic partnerships. The company needs to be mindful of competition and funding constraints.
Peer Comparison
Sources and Disclaimers
Data Sources:
- GeoVax Labs Inc. SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is dynamic and may change rapidly. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeoVax Labs Inc
Exchange NASDAQ | Headquaters Smyrna, GA, United States | ||
IPO Launch date 1999-04-09 | Chairman, President & CEO Mr. David Alan Dodd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.geovax.com |
Full time employees 17 | Website https://www.geovax.com | ||
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.